> In most other sub fields you don’t get to not publish if exactly one endpoint never comes to pass. I know I didn’t have something like that, and most of my non crystallographer friends didn’t.
How is this a problem unique to structural biology? In every subfield we're hoping to publish interesting results, and that endpoint is defined by the nature of the field. As a geneticist, in the early 90s, sequencing & characterizing a single bacterial gene would have been the focus of an ambitious PhD thesis and would yield multiple papers. Sequencing at that time period had a dozen points of failure and high risk to set as the goal for a thesis. Today, sequencing a whole genome is unlikely to yield a single publication. If you're setting the ability to crystallize as the single point of failure endpoint, that logic applies to every subfield. We all have something that could potentially derail our plans, and I fail to see how structural biology is unique in that respect.
> There’s a lot of structural biology apologists here in this thread. Happy to crap on DeepMind but not ready to take criticism of their own field.
I'm not a structural biologist - I'm a Geneticist who disagrees with your characterization of SB. The issues you've mentioned are not unique to SB, but apply to pretty much all subfields. I see grad students in general lament their life choices when their cell culture fails, their mice die, protocols just don't work, or their results just don't make sense.